No. This is incorrect. IMUN did not acquire patents from Cytocom. IMUN acquired patents (I believe in 2012) from Dr. Bihari. Look him up on Youtube. There are videos of him talking about low dose naltrexone. His vision was always to commercialize LDN in Africa, but was not able to do it during his lifetime. Dr. Bihari passed away after 25 years of working with low dose naltrexone.
I'm not sure about this, but I believe it's possible that Noreen (the CEO of IMUN) might have been a patient of Dr. Bihari's (I do know that she is a LDN user), and when he passed away, I guess she shared his vision of trying to bring LDN into Africa (first) and IMUN acquired 42 patents from Dr. Bihari after his passing. I could be wrong about that though, I just kind of assumed that's the likely way that Noreen was able to find herself acquiring these patents (by being a patient of his first).
IMUN owns a 55% stake in Cytocom (I believe), and Cytocom is the subsidiary of IMUN that plans to commercialize LDN in the United States in the future. From my understanding, the business plan all along was to get into Africa first, so that LDN becomes established and proven as a successful drug before attempting to get into the United States. It would be easier to get through the FDA in the US after the drug has a proven track record in Africa. As it currently stands, big pharma is against LDN because it is a more effective and CHEAPER drug than its competitors. Big pharma companies will essentially lose a ton of money if LDN is ever FDA approved in the United States, as LDN can replace multiple more expensive drugs for multiple different diseases.
News 
Market Data 
Discover 
